Corbus Pharmaceuticals Holdings, Inc.

NasdaqCM:CRBP Stok Raporu

Piyasa değeri: US$203.8m

Corbus Pharmaceuticals Holdings Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Corbus Pharmaceuticals Holdings has been growing earnings at an average annual rate of 18.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 85.2% per year.

Anahtar bilgiler

18.5%

Kazanç büyüme oranı

35.9%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı-85.2%
Özkaynak getirisi-27.9%
Net Marjn/a
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Jan 30

Corbus Pharmaceuticals GAAP EPS of -$0.11

Aug 09

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Using Too Much Debt?

Nov 19
Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Using Too Much Debt?

Here's Why Shareholders Should Examine Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package More Closely

Jun 12
Here's Why Shareholders Should Examine Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package More Closely

Should Shareholders Reconsider Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package?

May 14
Should Shareholders Reconsider Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package?

What Kind Of Shareholders Hold The Majority In Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Shares?

Mar 11
What Kind Of Shareholders Hold The Majority In Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Shares?

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Weighed On By Its Debt Load?

Feb 04
Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Weighed On By Its Debt Load?

Corbus Pharmaceuticals: Down But Not Out

Jan 29

Have Insiders Been Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares This Year?

Jan 09
Have Insiders Been Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares This Year?

Corbus's lenabasum shows benefit in autoimmune disorder

Nov 09

Gelir ve Gider Dağılımı

Corbus Pharmaceuticals Holdings nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqCM:CRBP Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 240-35140
31 Mar 240-34140
31 Dec 230-45140
30 Sep 230-47150
30 Jun 230-46160
31 Mar 230-51170
31 Dec 220-42190
30 Sep 220-42180
30 Jun 220-35200
31 Mar 220-39200
31 Dec 211-46200
30 Sep 212-44220
30 Jun 213-77240
31 Mar 213-98260
31 Dec 204-111280
30 Sep 206-129290
30 Jun 207-115270
31 Mar 2036-75250
31 Dec 1936-71240
30 Sep 1935-62210
30 Jun 1934-56190
31 Mar 196-70170
31 Dec 185-56130
30 Sep 183-49120
30 Jun 183-41110
31 Mar 182-37100
31 Dec 172-3290
30 Sep 173-2990
30 Jun 173-2890
31 Mar 173-2580
31 Dec 162-2060
30 Sep 162-1550
30 Jun 161-1240
31 Mar 161-1040
31 Dec 151-940
30 Sep 150-830
30 Jun 150-630
31 Mar 150-420
31 Dec 140-310
30 Sep 140-210
30 Jun 140-110
31 Mar 140-100

Kaliteli Kazançlar: CRBP is currently unprofitable.

Büyüyen Kar Marjı: CRBP is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: CRBP is unprofitable, but has reduced losses over the past 5 years at a rate of 18.5% per year.

Büyüme Hızlandırma: Unable to compare CRBP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: CRBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Özkaynak Getirisi

Yüksek ROE: CRBP has a negative Return on Equity (-27.86%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin